Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
NCT05226507 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Conditions Studied
Interventions
- DRUG NXP800
Study Locations (20)
Florida
- Florida Cancer Specialists South — Fort Myers
- Mount Sinai Comprehensive Cancer Center — Miami Beach
- Florida Cancer Specialists Research North — St. Petersburg
- Florida Cancer Specialists Research East — West Palm Beach
Oklahoma
- OU Health Stephenson Cancer Center — Oklahoma City
- Oklahoma Cancer Specialists and Research Institute — Tulsa
Texas
- Texas Oncology — Fort Worth
- The University of Texas MD Anderson Cancer Center — Houston
Arizona
- Honor Health — Phoenix
California
- UC San Diego Health - Moores Cancer Center — La Jolla
Colorado
- University of Colorado Cancer Center — Aurora
Connecticut
- Yale Gynecologic Oncology — New Haven
Iowa
- University of Iowa — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05226507
The ClinicalTrials.gov registry entry for NCT05226507 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvectis Pharma, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 8 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention — of which NXP800 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05226507 reports 20 study locations spanning 15 distinct geographic areas — top geographies include Florida, Oklahoma, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05226507 about?
NCT05226507 is a clinical study titled "A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer". The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
What is the current status of trial NCT05226507?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-12-31. Estimated completion is 2025-12.
What conditions does trial NCT05226507 study?
This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumor, Ovarian Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Clear Cell Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05226507?
The interventions under investigation include: NXP800 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05226507?
This trial is sponsored by Nuvectis Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05226507 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.